Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease

被引：9

作者：

McMahon, Gearoid M. ^{[1
,2
]}

Singh, Ajay K. ^{[1
,2
]}

机构：

[1] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

来源：

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION | 2019年 / 28卷 / 06期

关键词：

anemia; dialysis; erythropoietin; hypoxia-inducible factor; HYPOXIA-INDUCIBLE FACTORS; ERYTHROPOIETIN-PRODUCING CELLS; ROXADUSTAT FG-4592; IRON HOMEOSTASIS; EPOETIN-ALPHA; HIF-ALPHA; GSK1278863; HEMATOCRIT; GENE; HEMOGLOBIN;

D O I：

10.1097/MNH.0000000000000554

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of review Prolyl-hydroxylase inhibitors are a novel class of orally administered drugs that are under development for the treatment of anemia in patients with chronic kidney disease. This review discusses the biology of these drugs and their target - hypoxia-inducible factor and potential advantages and disadvantages of these therapies. Finally, we will discuss current trials in patients with both chronic kidney disease and end-stage renal disease. Recent findings Recent smaller studies have found that prolyl-hydroxylase are as effective as erythropoietin in treating anemia of chronic kidney disease. We do not yet know if they have the same cardiovascular and cancer-related risk profile and these questions will be answered by large phase III trials that are ongoing. Although prolyl hydroxylase inhibitors have much potential, questions remain regarding their efficacy and safety. Should these concerns prove to be unfounded, the treatment of anemia in chronic kidney disease will likely be transformed over the next decade.

引用

页码：600 / 606

页数：7

共 50 条

[1] Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
Cases, A.
Vera, M.
Ojeda, R.
Gorriz, J. L.
[J]. DRUGS OF THE FUTURE, 2018, 43 (01) : 23 - 33
[2] HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
Wyatt, Christina M.
Drueke, Tilman B.
[J]. KIDNEY INTERNATIONAL, 2016, 90 (05) : 923 - 925
[3] Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease
Wyatt, Christina M.
Drueke, Tilman B.
[J]. KIDNEY INTERNATIONAL, 2020, 97 (04) : 639 - 642
[4] Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?
Locatelli, Francesco
Del Vecchio, Lucia
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (06) : 926 - 932
[5] Hypoxia-inducible factor?prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
Haase, Volker H.
[J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 8 - 25
[6] Prolyl-hydroxylase domain inhibitors in chronic kidney disease, a promising alternative for erythropoiesis-stimulating agent
Rubinsztajn, A.
Fouque, D.
[J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 76 : 28 - 30
[7] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease
Bartnicki, Piotr
[J]. BIOMEDICINES, 2024, 12 (08)
[8] Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza, Ernane
Cho, Katherine H.
Harris, Shelby T.
Flindt, Naomi R.
Watt, Richard K.
Pai, Amy Barton
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 831 - 844
[9] Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
Sugahara, Mai
Tanaka, Tetsuhiro
Nangaku, Masaomi
[J]. KIDNEY INTERNATIONAL, 2017, 92 (02)
[10] Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
Kurata, Yu
Tanaka, Tetsuhiro
Nangaku, Masaomi
[J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04): : 414 - 422

← 1 2 3 4 5 →